News

Dementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight
Dementia associated with Alzheimer’s disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population ...
Fierce Pharma2d
Bristol Myers, Pfizer offer Eliquis at a discount through DTC online program
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
Neurology Advisor3d
FDA Approves New Dosing Regimen for Kisunla in Alzheimer Disease
The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.
Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round
Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...
BioSpace3d
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
Cantech Letter4d
Health Canada Approves Lilly’s Omvoh® (mirikizumab) for Crohn’s Disease; New Citrate-Free Formulation
Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...
The Malaysian Reserve6d
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly ...